Table 1.
Summary of Post-marketing Survey which was Conducted to Hepatocellular Carcinoma (HCC) or Thyroid Cancer (TC) Patients Administered Lenvatinib Cited from Guide to Proper Use of Lenvatinib.
| Age | Sex | Primary disease |
Time from starting lenvatinib to the onset of drug-induced interstitial pneumonia (day) |
Outcome | Time from onset to outcome (day) |
|---|---|---|---|---|---|
| 70s | M | HCC | 28 | death | 3 |
| 70s | M | HCC | 43 | death | 16 |
| 70s | M | HCC | 46 | death | 27 |
| 50s | M | HCC | 9 | death | 3 |
| 70s | M | TC | 16 | death | 3 |
| 60s | M | HCC | 40 | recovered | 6 |
| 70s | F | HCC | 6 | recovered | unknown |
| 70s | M | HCC | 87 | recovered | 2 |
| 80s | M | HCC | 109 | recovered | 17 |
| 70s | M | HCC | 63 | recovered | 103 |
| 70s | F | HCC | 125 | recovered | 11 |
| 60s | M | TC | 51 | recovered | 9 |
| 60s | M | TC | 30 | recovered | 167 |